Further investigation of the customer issue included a review of the complaint text, a search for similar complaints, in-house testing and a review of labeling.Ticket searches determined that there is normal complaint activity for the likely cause lot number.Tracking and trending report review for the architect havab-igm assay determined that there are no related non-statistical or adverse trends.The clinical sensitivity of reagent lot 77622li00 was evaluated by testing one commercially available seroconversion panel.The seroconversion panel results were compared with historical architect havab igm data provided by the panel manufacturer.The complaint lot detected the same first bleed as (b)(6) with comparable (b)(6) values.Manufacturing documentation for the likely cause lot did not identify any issues associated with the complaint issue.Additionally, labeling was reviewed and sufficiently addresses the customer's issue.Based on the available information, no systemic issue or deficiency of the architect havab-igm assay was identified.
|